Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)
Latest Information Update: 11 Jul 2025
At a glance
- Drugs Recombinant staphylokinase Supergene (Primary)
- Indications Pulmonary embolism
- Focus Registrational; Therapeutic Use
- Acronyms FORPE-2
- Sponsors Supergene
Most Recent Events
- 19 Jun 2024 Status changed from not yet recruiting to recruiting.
- 17 Apr 2024 New trial record